Floatz logo

Epirubicin

Indolent B-Cell Non-Hodgkin Lymphoma

University of WashingtonPhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Indolent B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
University of Washington
Phase 2BB
(+)-VINCRISTINE
Fate Therapeutics
Phase 2BB
Polatuzumab Vedotin
University of Washington
Phase 2BB
cc-5013
Antengene Corporation
Phase 2BB
DEXAMETHASONE
Antengene Corporation
Phase 2BB

View all 15 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →